Dilip Shanghvi, managing director of Sun Pharma told analysts at the company’s earnings call on Tuesday that the drug maker is interested in bolt-on acquisitions in emerging markets, small to medium size businesses in Europe and also businesses with either existing products or products close to market in the US.
